GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhende Medical Co 603301.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

85.00

+0.29%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥4.33bn

FY2016FY2025

Net income

CN¥260.8m

FY2016FY2025

Free cash flow

−CN¥11.7m

FY2016FY2025

Shareholders' equity

CN¥5.69bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥4.33bnCN¥4.26bnCN¥4.13bnCN¥6.14bnCN¥5.09bnCN¥10.40bnCN¥1.87bnCN¥1.43bnCN¥1.31bnCN¥1.03bn
Gross profitCN¥1.47bnCN¥1.41bnCN¥1.28bnCN¥2.07bnCN¥1.74bnCN¥4.83bnCN¥591.6mCN¥440.1mCN¥382.1mCN¥323.2m
Research and developmentCN¥142.4mCN¥135.5mCN¥138.9mCN¥227.0mCN¥153.1mCN¥259.7mCN¥51.0mCN¥56.9mCN¥43.7mCN¥31.1m
Operating incomeCN¥388.3mCN¥491.8mCN¥225.9mCN¥812.8mCN¥822.0mCN¥3.54bnCN¥200.3mCN¥153.4mCN¥148.0mCN¥106.0m
Net incomeCN¥260.8mCN¥385.2mCN¥198.4mCN¥679.9mCN¥595.9mCN¥2.55bnCN¥156.9mCN¥130.2mCN¥121.8mCN¥82.8m
Diluted earnings per share0.971.480.722.502.6711.690.780.640.820.31

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥8.40bnCN¥7.58bnCN¥7.27bnCN¥7.90bnCN¥6.42bnCN¥6.40bnCN¥2.67bnCN¥1.85bnCN¥1.29bnCN¥1.13bn
Cash and short-term investments—CN¥828.4mCN¥1.21bnCN¥2.17bnCN¥1.36bnCN¥2.01bnCN¥686.7mCN¥302.4mCN¥114.4mCN¥63.5m
Total liabilitiesCN¥2.44bnCN¥1.68bnCN¥1.66bnCN¥2.14bnCN¥1.98bnCN¥1.93bnCN¥1.27bnCN¥725.3mCN¥733.7mCN¥689.7m
DebtCN¥383.1mCN¥551.3mCN¥459.5mCN¥564.3mCN¥848.4mCN¥453.5mCN¥714.6mCN¥365.7mCN¥410.0mCN¥390.0m
Shareholders' equityCN¥5.69bnCN¥5.64bnCN¥5.37bnCN¥5.54bnCN¥4.07bnCN¥4.18bnCN¥1.36bnCN¥1.12bnCN¥559.2mCN¥437.5m
Shares outstanding270m260m275m272m223m218m202m203m149m270m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥538.5mCN¥461.1mCN¥452.1mCN¥1.25bnCN¥817.6mCN¥3.12bnCN¥197.8mCN¥20.2mCN¥182.3mCN¥138.6m
Capital spending−CN¥550.2m−CN¥769.7m−CN¥599.2m−CN¥754.1m−CN¥695.5m−CN¥1.09bn−CN¥273.8m−CN¥226.7m−CN¥144.4m−CN¥159.2m
Free cash flow−CN¥11.7m−CN¥308.5m−CN¥147.1mCN¥491.9mCN¥122.2mCN¥2.03bn−CN¥76.0m−CN¥206.5mCN¥37.9m−CN¥20.7m
Dividends paid−CN¥201.5m−CN¥159.4m−CN¥423.7m−CN¥164.3m−CN¥522.6m−CN¥60.2m−CN¥35.0m−CN¥21.0m−CN¥21.4m−CN¥22.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.22bnCN¥1.00bnCN¥1.15bnCN¥1.08bnCN¥1.11bnCN¥991.6mCN¥1.14bnCN¥1.08bn
Gross profitCN¥423.4mCN¥345.9mCN¥388.1mCN¥377.7mCN¥362.9mCN¥339.9mCN¥324.9mCN¥386.6m
Operating incomeCN¥127.6mCN¥77.2mCN¥106.1mCN¥91.8mCN¥100.0mCN¥62.5mCN¥95.9mCN¥194.6m
Net incomeCN¥89.3mCN¥54.4mCN¥57.6mCN¥75.4mCN¥76.5mCN¥51.2mCN¥77.7mCN¥146.4m
Diluted earnings per share0.330.200.210.280.280.190.300.56
Cash from operations———CN¥101.0mCN¥188.0m−CN¥27.0m—CN¥53.0m
Capital spending−CN¥65.0m−CN¥80.0m−CN¥130.0m−CN¥109.0m−CN¥111.0m−CN¥199.0m−CN¥274.0m−CN¥189.0m
Free cash flow———−CN¥8.0mCN¥77.0m−CN¥226.0m—−CN¥136.0m
Total assetsCN¥8.34bnCN¥8.36bnCN¥8.40bnCN¥8.40bnCN¥8.38bnCN¥8.13bnCN¥7.58bnCN¥7.87bn
Cash and short-term investments———CN¥1.08bnCN¥1.45bnCN¥1.22bnCN¥828.4mCN¥1.11bn
DebtCN¥381.8mCN¥381.1mCN¥383.1mCN¥1.01bnCN¥1.42bnCN¥1.09bnCN¥549.8mCN¥934.4m
Shareholders' equityCN¥5.68bnCN¥5.72bnCN¥5.69bnCN¥5.70bnCN¥5.63bnCN¥5.71bnCN¥5.64bnCN¥5.58bn

Financial ratios

Data as of 24 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin33.9%33.2%30.9%33.8%34.1%46.5%
Operating margin9.0%11.5%5.5%13.2%16.1%34.0%
Net margin6.0%9.0%4.8%11.1%11.7%24.5%
Return on equity4.6%6.8%3.7%12.3%14.7%61.0%
Return on assets3.1%5.1%2.7%8.6%9.3%39.8%
Free cash flow yield5.1%6.0%4.9%9.4%8.6%24.6%
Revenue growth1.5%3.3%-32.8%20.5%-51.0%456.7%
Earnings growth-32.3%94.1%-70.8%14.1%-76.6%1525.0%
Current ratio1.58x2.28x2.32x2.72x1.99x2.50x
Debt to equity0.07x0.10x0.08x0.09x0.20x0.17x
Equity ratio67.7%74.5%73.8%70.2%63.3%65.4%
Interest coverage12.33x15.56x7.31x23.51x30.29x154.87x
R&D as a share of sales3.3%3.2%3.4%3.7%3.0%2.5%
Buybacks as a share of market value-3.5%5.1%-1.0%-21.6%-2.4%-7.9%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-11.0%-16.1%15.5%
Operating income-21.8%-35.7%16.8%
Net income-27.3%-36.6%12.7%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin33.5%33.1%37.3%36.2%
Operating margin10.2%10.2%18.3%17.0%
Net margin7.5%8.1%13.6%12.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings72.914.933.915.219.35.320.025.3
Price to sales4.41.31.61.72.31.31.72.3

Dividends and splits

Per share, in the currency the company pays

Paid for 7 years. Last went ex-dividend on 18 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.300.650.501.500.602.300.3070.179
  • 7-for-5 split · 8 Jun 2020
  • 7-for-5 split · 24 May 2019

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.